Sunshine Lake Pharma Research Institute was established in 2005. Driven by the dual engines of "Innovation" and "Internationalization", it focuses on the global development and commercialization of innovative small molecule drugs, innovative biologics and biosimilars, and novel formulations including first generics, spanning multiple fields such as infectious diseases like hepatitis B and C, oncology like esophageal cancer, and endocrine and metabolic diseases like diabetes.

Approved by the Ministry of Science and Technology of the PRC in September 2015 as the "State Key Laboratory of Anti-Infective Drug Development" the laboratory underwent restructuring and upgrading in 2022, and was officially designated the "State Key Laboratory of Anti-Infective Drug Development" in 2023, with Sunshine Lake Pharma Co., Ltd. as its primary supporting institution. Current major research includes: persistent viral pathogenesis and novel drug development; emergent viral pathogenesis (e.g. COVID-19 virus) and novel drug development; bacterial resistance mechanisms and novel drug development; pathogenesis of infectious disease complications and novel drug development.

chemical drugs discovery, biologics research and development, innovative formulation technologies, possessing fully independent research and development capabilities